Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 2, 2016, Pages 126-129

  Disanto, Giulio ^a,b   Adiutori, Rocco ^a   Dobson, Ruth ^a   Martinelli, Vittorio ^c   Costa, Gloria Dalla ^c   Runia, Tessel ^d   Evdoshenko, Evgeniy ^e   Thouvenot, Eric ^f,g   Trojano, Maria ^h   Norgren, Niklas ⁱ   Teunissen, Charlotte ^j   Kappos, Ludwig ^k   Giovannoni, Gavin ^a   Kuhle, Jens ^a,k  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Ospedale Civico Lugano   (Switzerland)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e City Clinical Hospital No 25   (Russian Federation)

^f INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^g DEPARTMENT OF NEUROLOGY   (France)

^h UNIVERSITY OF BARI   (Italy)

ⁱ UmanDiagnostics AB   (Sweden)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; NEUROFILAMENT LIGHT CHAIN PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; BRAIN DAMAGE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CONVERSION TIME; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FAST CONVERTER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NON CONVERTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CODING; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AXON; BLOOD; FOLLOW UP; PATHOLOGY; PREDICTIVE VALUE;

ADULT; AXONS; BIOMARKERS; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PREDICTIVE VALUE OF TESTS;

EID: 84958873094     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309690     Document Type: Article

References (16)

1. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol 2014; 13: 113-26.
2. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013; 19: 1597-603.
3. Lim ET, Sellebjerg F, Jensen CV, et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005; 11: 532-6.
4. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009; 72: 1322-9.
5. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 2013; 8: E75091.
6. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2015; 86: 273-9.
7. Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler 2015 Feb 13. pii: 1352458514568827 (Epub ahead of print).
8. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
9. Andersson M, varez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897-902.
10. Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 467-72.
11. Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 2010; 68: 806-15.
12. Brettschneider J, Petzold A, Junker A, et al. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006; 12: 143-8.
13. Khalil M, Enzinger C, Langkammer C, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19: 436-42.
14. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76: 1206-13.
15. Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586-90.
16. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287-92.